Clinical Trial Update: The Impact of Rosiglitazone on Regression of Atherosclerosis [NA]

View source ↗

Summary

A clinical trial evaluating rosiglitazone for regression of atherosclerosis in diabetes patients is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Diabetes Mellitus

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Diabetes Mellitus, Atherosclerosis | NA | Status: SUSPENDED